Navigation Links
FDA Grants Priority Review for ACIPHEX(R) (rabeprazole sodium) sNDA for Short-Term Treatment of GERD in Adolescents
Date:2/29/2008

estinal disorders and oncology/critical care.

Eisai Corporation of North America supports the activities of its operating companies in North America. These operating companies include: Eisai Research Institute of Boston, Inc., a discovery operation with strong organic chemistry capabilities; Morphotek, Inc., a biopharmaceutical company specializing in the development of therapeutic monoclonal antibodies; Eisai Medical Research Inc., a clinical development group; Eisai Inc., a commercial operation with manufacturing and marketing/sales functions; MGI PHARMA, INC., an R&D and commercial operation with manufacturing and marketing/sales functions; and Eisai Machinery U.S.A., which markets and maintains pharmaceutical manufacturing machinery.
For more information about Eisai, please visit http://www.eisai.com.

ACIPHEX is a registered trademark of Eisai Co., Ltd.

Coumadin is a registered trademark of Bristol-Myers Squibb Pharma Company.


'/>"/>
SOURCE Eisai Corporation of North America
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. FDA Grants Priority Review for Daiichi Sankyo, Lilly Drug, prasugrel
2. FDA Grants Approval to Extend U.S. Enrollment and Clinical Trial
3. NTMir Announces Research Grants for Epidemiology and Household Water as Source of Infection
4. Ethics Group Asks USAID Inspector General to Investigate Legality of Grants to Soros Groups
5. Chinese SFDA Grants Immtech Fast Track Status
6. US FDA Grants Orphan Drug Status to Immtechs Pafuramidine for Treatment of African Sleeping Sickness
7. Inclusion of Six-Year Overall Survival Data in the Eloxatin(R) (oxaliplatin injection) Prescribing Information Granted FDA Priority Review
8. Advanced Life Sciences Collaborates with U.S. Government to Study Cethromycin as Treatment for Anthrax and Other High-Priority Biodefense Agents
9. Micromet Announces the Publication of BiTE Antibody Review in Drugs of the Future
10. FDA Extends Review of Genasense(R) NDA Appeal in Chronic Lymphocytic Leukemia
11. Halozyme Therapeutics Announces Peer-Reviewed Publications of the INFUSE-LR Clinical Trial Results and Clinical Practice Experience With Hylenex
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)... YORK , July 6, 2015 E-QURE ... Chairman, will present live at VirtualInvestorConferences.com on July 9, ... EDT LINK: http://tinyurl.com/e-qure-presentation This ... are invited to ask the company questions in real-time ... the association,s "virtual trade booth." If attendees are not ...
(Date:7/6/2015)... Array BioPharma,s (NASDAQ:   ARRY) wholly-owned ... at the 2015 ESMO World Congress of Gastrointestinal ... data were shared from a Phase 1b trial ... 2 expansion of that trial testing the combination ... or without the addition of alpelisib (BYL719) ...
(Date:7/6/2015)... FRANCISCO, Calif. , July 6, 2015 ... pharmaceutical company, and Oculeve, a development-stage medical device company ... today announced that they have entered into an agreement ... transaction.  Under the terms of the agreement, Allergan will ... commercialization milestone payments related to Oculeve,s lead development program ...
Breaking Medicine Technology:E-QURE Corp to Webcast, Live, at VirtualInvestorConferences.com July 9 2Encorafenib-Based Regimens Show Promising Clinical Activity In BRAF-Mutant Colorectal Cancer Patients 2Encorafenib-Based Regimens Show Promising Clinical Activity In BRAF-Mutant Colorectal Cancer Patients 3Encorafenib-Based Regimens Show Promising Clinical Activity In BRAF-Mutant Colorectal Cancer Patients 4Allergan to Acquire Oculeve Dry Eye Disease Development Programs 2Allergan to Acquire Oculeve Dry Eye Disease Development Programs 3Allergan to Acquire Oculeve Dry Eye Disease Development Programs 4
... Savient Pharmaceuticals, Inc. (Nasdaq: SVNT ) today announced ... gout will be reviewed by the Arthritis Advisory Committee appointed ... 5, 2009 as required for a drug of a new ... the FDA on October 31, 2008 seeking approval to market ...
... 28 Cell Therapeutics (CTI),(Nasdaq and MTA: ... from its pivotal phase III EXTEND (PIX301) ... relapsed aggressive non-Hodgkin,s lymphoma,(NHL) treated with pixantrone ... survival, compared with other,single-agent chemotherapeutic agents ...
Cached Medicine Technology:Savient Announces FDA's Advisory Panel to Review Pegloticase for Treatment-Failure Gout Patients 2Savient Announces FDA's Advisory Panel to Review Pegloticase for Treatment-Failure Gout Patients 3Savient Announces FDA's Advisory Panel to Review Pegloticase for Treatment-Failure Gout Patients 4Pixantrone Increases Progression-Free Survival by 81% Compared to Standard Chemotherapeutic Agents in Phase III Relapsed Aggressive non-Hodgkin's Lymphoma Trial 2Pixantrone Increases Progression-Free Survival by 81% Compared to Standard Chemotherapeutic Agents in Phase III Relapsed Aggressive non-Hodgkin's Lymphoma Trial 3Pixantrone Increases Progression-Free Survival by 81% Compared to Standard Chemotherapeutic Agents in Phase III Relapsed Aggressive non-Hodgkin's Lymphoma Trial 4
(Date:7/6/2015)... Chester, NJ (PRWEB) , ... July 06, 2015 ... ... CancerHopeNetwork.org. The redesigned site allows newly-diagnosed cancer patients, caregivers and medical professionals to ... who has survived the same cancer. , “Receiving a cancer diagnosis is often ...
(Date:7/6/2015)... ... July 06, 2015 , ... ... Associates has once again teamed up with Family Emergency Shelter Coalition (FESCO) and ... toward self-sufficiency. FESCO was created especially to provide emergency services and support for ...
(Date:7/6/2015)... ... July 06, 2015 , ... With a new community program ... Livonia Save Our Youth and announced a new charity campaign to raise funds in ... alcohol and drug abuse. Livonia Save Our Youth is a coalition created especially to ...
(Date:7/6/2015)... ... ... Dr. Lawrence Green is now offering the newly FDA-approved Kybella injectable to his ... to dissolve fat cells and is the first of its kind to be approved ... known as a double chin. Dr. Green participated in clinical trials for Kybella and ...
(Date:7/6/2015)... ... July 06, 2015 , ... Diabetes affects many of ... than 29 million Americans have diabetes, the majority of which are Type 2. However, ... or more than one in three, have prediabetes (abnormally high blood sugar levels). Without ...
Breaking Medicine News(10 mins):Health News:Cancer Hope Network Launches Upgraded Website to Support Cancer Patients, Caregivers 2Health News:Carlson & Associates Insurance Agency and Nonprofit Family Emergency Shelter Coalition (FESCO) Initiate New Charity Campaign in Alameda County, CA to Provide for Homeless 2Health News:Carlson & Associates Insurance Agency and Nonprofit Family Emergency Shelter Coalition (FESCO) Initiate New Charity Campaign in Alameda County, CA to Provide for Homeless 3Health News:Bowker Insurance Group and Nonprofit Livonia Save Our Youth Initiate New Charity Campaign in Livonia, MI to Provide for The Health and Safety of The Communities’ Youth 2Health News:Bowker Insurance Group and Nonprofit Livonia Save Our Youth Initiate New Charity Campaign in Livonia, MI to Provide for The Health and Safety of The Communities’ Youth 3Health News:Rockville, MD Practice Now Offering New FDA-Approved Non-Surgical Double Chin Treatment 2Health News:115 Million in the U.S. could beat diabetes with the help of a new app 2
... experts, adults aged over 40 may have COPD (Chronic ... ,COPD is a general term used for ... bronchitis. Smoking is considered to be the main cause. ... and getting out of breath during exercise or exertion. ...
... the most common respiratory disease after the common cold. ... teen-agers who smoke, have nearly four times the risk ... who did not smoke. Similarly, children whose mothers smoked ... ,Lead researcher Frank Gilliland, M.D., Ph.D., professor of ...
... are angry, even igniting life and death situations, to ... ,With the help of special instruments, called implantable ... connection between emotions and heart rhythms in a group ... check on the heart rhythms and are programmed to ...
... whether from holiday feasts or rich desserts or alcoholic beverages ... ,Heartburn – generally caused by naturally occurring acids splashing ... a characteristic burning sensation that sufferers describe as rolling up ... this process. ,“Most of the time heartburn is ...
... Despite ground breaking and earth shaking research worldwide the leaders of ... out of their piggy banks to save// the poorest of the ... era which seems to offer little in the form of ... illness in higher socio economic groups. ,Statistics reveal ...
... celebrate the 30th anniversary of the Great American Smokeout ... American Smokeout over the past three decades has always ... as well as the challenges of quitting. ... urged to call the American Cancer Society's Quitline, which ...
Cached Medicine News:Health News:Teen-age Smokers at Higher Risk Of Developing Asthma 2Health News:Teen-age Smokers at Higher Risk Of Developing Asthma 3Health News:Holiday Season Could Ring in “Heartburn Season 2Health News:Holiday Season Could Ring in “Heartburn Season 3Health News:Poor diabetics: bitter times and worse times with no sweet respite 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: